Elan Pharmaceuticals

E133121

Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (2)

Label Occurrences
Elan Drug Technologies 1
Elan Pharmaceuticals canonical 1

Statements (48)

Predicate Object
instanceOf analgesic drug
biotechnology company
drug delivery business unit
monoclonal antibody
monoclonal antibody drug
pharmaceutical company
pharmaceutical company
acquiredBy Perrigo
acquisitionCompletedIn 2013
coDevelopedWith Biogen
surface form: Biogen Idec
collaboratedWith Johnson & Johnson
Wyeth
country Ireland
defunctSince 2013
developed Tysabri
bapineuzumab
developedFor Alzheimer's disease
experienced Tysabri market withdrawal in 2005
focusesOn autoimmune diseases
neurological diseases
foundedIn 1969
founder Donal E. R. Geaney
hadControversy Tysabri safety concerns
hadEmployeeCountApprox 1700
hadProduct Prialt
hadSubsidiary Elan Pharmaceuticals self-linksurface differs
surface form: Elan Drug Technologies
headquartersLocation Dublin
industry biotechnology
pharmaceuticals
knownFor drug delivery technologies
laterResumed Tysabri marketing
listedOn Irish Stock Exchange
operatedIn Europe
Ireland
United States of America
surface form: United States
researchArea Alzheimer's disease
Parkinson's disease
autoimmune disorders
multiple sclerosis
specializesIn central nervous system disorders
neurodegenerative diseases
status defunct
stockExchange New York Stock Exchange
tickerSymbol ELN
tradedAs NYSE:ELN
treats Crohn's disease
multiple sclerosis
usedFor severe chronic pain

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Tysabri developedBy Elan Pharmaceuticals
Elan Pharmaceuticals hadSubsidiary Elan Pharmaceuticals self-linksurface differs
this entity surface form: Elan Drug Technologies